Tianan Pharmaceutical Co Stock Revenue

TNPH Stock  USD 0.01  0.00  0.00%   
Tianan Pharmaceutical Co fundamentals help investors to digest information that contributes to Tianan Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Tianan Pink Sheet. The fundamental analysis module provides a way to measure Tianan Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tianan Pharmaceutical pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Tianan Pharmaceutical Co Company Revenue Analysis

Tianan Pharmaceutical's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Revenue

 = 

Money Received

-

Discounts and Returns

More About Revenue | All Equity Analysis

Current Tianan Pharmaceutical Revenue

    
  10.65 M  
Most of Tianan Pharmaceutical's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tianan Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Competition

Based on the latest financial disclosure, Tianan Pharmaceutical Co reported 10.65 M of revenue. This is 99.86% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The revenue for all United States stocks is 99.89% higher than that of the company.
Tianan Pharmaceutical Co is currently regarded number one company in revenue category among its peers. Market size based on revenue of Drug Manufacturers—Specialty & Generic industry is at this time estimated at about 11.66 Million. Tianan Pharmaceutical totals roughly 10.65 Million in revenue claiming about 91% of equities under Drug Manufacturers—Specialty & Generic industry.

Tianan Fundamentals

About Tianan Pharmaceutical Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Tianan Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tianan Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tianan Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Tianan Pink Sheet

Tianan Pharmaceutical financial ratios help investors to determine whether Tianan Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Tianan with respect to the benefits of owning Tianan Pharmaceutical security.